Effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic rats
Though osteoporosis is a significant cause of disability worldwide, treatment with pharmacologic agents decreases risk of fragility fracture. Though these treatments act through the bone remodeling system to improve bone mass, it is unclear if they alter the response of bone to mechanical loading at...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-06-01
|
Series: | Bone Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S235218721830010X |
id |
doaj-3cd125d351134d8ba2f45f54ab52ed6f |
---|---|
record_format |
Article |
spelling |
doaj-3cd125d351134d8ba2f45f54ab52ed6f2020-11-24T21:39:01ZengElsevierBone Reports2352-18722018-06-018115124Effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic ratsAmber Rath Stern0Xiaomei Yao1Yong Wang2Amanuel Berhe3Mark Dallas4Mark L. Johnson5Wei Yao6Donald B. Kimmel7Nancy E. Lane8Engineering Systems Inc., 3310 Green Park Circle, Charlotte, NC 28217, United States; University of Missouri – Kansas City, Mechanical Engineering, 5100 Rock Hill Rd., Kansas City, MO 64110, United StatesUniversity of Missouri – Kansas City, School of Dentistry, 650 E 25th St, Kansas City, MO 64108, United StatesUniversity of Missouri – Kansas City, School of Dentistry, 650 E 25th St, Kansas City, MO 64108, United StatesUniversity of Missouri – Kansas City, School of Dentistry, 650 E 25th St, Kansas City, MO 64108, United StatesUniversity of Missouri – Kansas City, School of Dentistry, 650 E 25th St, Kansas City, MO 64108, United StatesUniversity of Missouri – Kansas City, School of Dentistry, 650 E 25th St, Kansas City, MO 64108, United StatesMusculoskeletal Research Unit, Department of Medicine, University of California Davis Medical Center, Sacramento, CA 95817, United StatesDepartment of Physiological Sciences, University of Florida, Gainesville, FL 32610, United StatesMusculoskeletal Research Unit, Department of Medicine, University of California Davis Medical Center, Sacramento, CA 95817, United States; Corresponding author at: Endowed Professor of Medicine and Rheumatology, Director, Center for Musculoskeletal Health, 4625 2nd Avenue, Suite 1002, Sacramento, CA 95817, United States.Though osteoporosis is a significant cause of disability worldwide, treatment with pharmacologic agents decreases risk of fragility fracture. Though these treatments act through the bone remodeling system to improve bone mass, it is unclear if they alter the response of bone to mechanical loading at the level of the osteocyte. This pre-clinical study determined the relationship between microstructural bone tissue properties and osteocyte lacunar size and density to strain around osteocytes with standard osteoporosis treatment or sequential therapies. Six-month-old female ovariectomized (OVX) Sprague-Dawley rats were cycled through various sequences of pharmacological treatments [alendronate (Aln), raloxifene (Ral) and human parathyroid hormone-1,34 (PTH)] for three month intervals, over nine months. Linear nanoindentation mapping was used to determine Young's modulus in perilacunar and bone matrix regions around cortical bone osteocyte lacunae. Measurements of lacunar diameter and density were completed. Treatment-related differences in Young's modulus in the perilacunar and bone matrix regions were not observed. We confirmed previous data that showed that the bone matrix region was stiffer than the perilacunar matrix region. Whole bone material properties were correlated to perilacunar matrix stiffness. Finite element models predicted a range of mechanical strain amplification factors estimated at the osteocyte across treatment groups. In summary, though the perilacunar matrix near cortical osteocyte lacuna is not as stiff as bone matrix further away, osteoporosis treatment agents do not affect the stiffness of bone tissue near osteocyte lacunae. Keywords: Lacuna, Nanoindentation, Finite element model, Sequential treatment, PTH(1-34), Alendronate, Raloxifenehttp://www.sciencedirect.com/science/article/pii/S235218721830010X |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Amber Rath Stern Xiaomei Yao Yong Wang Amanuel Berhe Mark Dallas Mark L. Johnson Wei Yao Donald B. Kimmel Nancy E. Lane |
spellingShingle |
Amber Rath Stern Xiaomei Yao Yong Wang Amanuel Berhe Mark Dallas Mark L. Johnson Wei Yao Donald B. Kimmel Nancy E. Lane Effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic rats Bone Reports |
author_facet |
Amber Rath Stern Xiaomei Yao Yong Wang Amanuel Berhe Mark Dallas Mark L. Johnson Wei Yao Donald B. Kimmel Nancy E. Lane |
author_sort |
Amber Rath Stern |
title |
Effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic rats |
title_short |
Effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic rats |
title_full |
Effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic rats |
title_fullStr |
Effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic rats |
title_full_unstemmed |
Effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic rats |
title_sort |
effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic rats |
publisher |
Elsevier |
series |
Bone Reports |
issn |
2352-1872 |
publishDate |
2018-06-01 |
description |
Though osteoporosis is a significant cause of disability worldwide, treatment with pharmacologic agents decreases risk of fragility fracture. Though these treatments act through the bone remodeling system to improve bone mass, it is unclear if they alter the response of bone to mechanical loading at the level of the osteocyte. This pre-clinical study determined the relationship between microstructural bone tissue properties and osteocyte lacunar size and density to strain around osteocytes with standard osteoporosis treatment or sequential therapies. Six-month-old female ovariectomized (OVX) Sprague-Dawley rats were cycled through various sequences of pharmacological treatments [alendronate (Aln), raloxifene (Ral) and human parathyroid hormone-1,34 (PTH)] for three month intervals, over nine months. Linear nanoindentation mapping was used to determine Young's modulus in perilacunar and bone matrix regions around cortical bone osteocyte lacunae. Measurements of lacunar diameter and density were completed. Treatment-related differences in Young's modulus in the perilacunar and bone matrix regions were not observed. We confirmed previous data that showed that the bone matrix region was stiffer than the perilacunar matrix region. Whole bone material properties were correlated to perilacunar matrix stiffness. Finite element models predicted a range of mechanical strain amplification factors estimated at the osteocyte across treatment groups. In summary, though the perilacunar matrix near cortical osteocyte lacuna is not as stiff as bone matrix further away, osteoporosis treatment agents do not affect the stiffness of bone tissue near osteocyte lacunae. Keywords: Lacuna, Nanoindentation, Finite element model, Sequential treatment, PTH(1-34), Alendronate, Raloxifene |
url |
http://www.sciencedirect.com/science/article/pii/S235218721830010X |
work_keys_str_mv |
AT amberrathstern effectofosteoporosistreatmentagentsonthecorticalboneosteocytemicroenvironmentinadultestrogendeficientosteopenicrats AT xiaomeiyao effectofosteoporosistreatmentagentsonthecorticalboneosteocytemicroenvironmentinadultestrogendeficientosteopenicrats AT yongwang effectofosteoporosistreatmentagentsonthecorticalboneosteocytemicroenvironmentinadultestrogendeficientosteopenicrats AT amanuelberhe effectofosteoporosistreatmentagentsonthecorticalboneosteocytemicroenvironmentinadultestrogendeficientosteopenicrats AT markdallas effectofosteoporosistreatmentagentsonthecorticalboneosteocytemicroenvironmentinadultestrogendeficientosteopenicrats AT markljohnson effectofosteoporosistreatmentagentsonthecorticalboneosteocytemicroenvironmentinadultestrogendeficientosteopenicrats AT weiyao effectofosteoporosistreatmentagentsonthecorticalboneosteocytemicroenvironmentinadultestrogendeficientosteopenicrats AT donaldbkimmel effectofosteoporosistreatmentagentsonthecorticalboneosteocytemicroenvironmentinadultestrogendeficientosteopenicrats AT nancyelane effectofosteoporosistreatmentagentsonthecorticalboneosteocytemicroenvironmentinadultestrogendeficientosteopenicrats |
_version_ |
1725933147458109440 |